NCT01046539View on ClinicalTrials.gov

Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

January 31, 2010

Primary Completion Date

March 31, 2010

Study Completion Date

July 31, 2010

Conditions
Substance-Related Disorders
Interventions
DRUG

RDC-0313 + Buprenorphine

1 and 4 mg (1 dose for each) + 8 mg

DRUG

Placebo

0 mg

Trial Locations (1)

94143

Langley Porter Psychiatric Hospital, San Francisco

Sponsors

Collaborators (1)

Alkermes, Inc.
All Listed Sponsors
collaborator

Alkermes, Inc.

INDUSTRY

lead

National Institute on Drug Abuse (NIDA)

NIH